DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 9.446,032 B2 Madhukar Kodgule Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 9.446,032 B2 Madhukar Kodgule Et Al USOO9446032B2 (12) United States Patent (10) Patent No.: US 9.446,032 B2 Madhukar Kodgule et al. (45) Date of Patent: Sep. 20, 2016 (54) METHODS FOR TREATING A61K 9/1605; A61 K9/2072; A61 K9/2086; CARDOVASCULAR DISORDERS A61K 9/1652: A61K 9/167: A61 K9/20: A61 K9/2004; A61 K9/2054: A61 K9/48 (75) Inventors: Mandar Madhukar Kodgule, USPC .................................................. 424/465-489 Aurangabad (IN); Premchand See application file for complete search history. Dalichandji Nakhat, Noida (IN); Amit Gupta, Ahmedabad (IN); Girish (56) References Cited Kumar Jain, Aurangabad (IN) U.S. PATENT DOCUMENTS (73) Assignee: WOCKHARDT LIMITED, Bandra 4.942,040 A * 7/1990 Ragnarsson ......... A61K9/2081 East, Mumbai (IN) 424/459 2005/0032879 A1 2/2005 Okarter et al. (*) Notice: Subject to any disclaimer, the term of this 2008/0233190 A1* 9, 2008 Solomon .............. A61K 9.2072 patent is extended or adjusted under 35 424/467 U.S.C. 154(b) by 94 days. FOREIGN PATENT DOCUMENTS (21) Appl. No.: 14/240,380 CN 101.249083. A 8, 2008 (22) PCT Filed: Aug. 23, 2012 WO WO2007/O105O1 A2 1, 2007 WO WO 2007O 105O1 A2 * 1, 2007 ........ A61K 9,2081 (86). PCT No.: PCT/B2012/0542.57 WO WO2007/110753 A2 9, 2007 S 371 (c)(1), OTHER PUBLICATIONS (2), (4) Date: May 15, 2014 Efficacy and tolerability of a fixed-dose combination of metoprolol extended releasefamlodipine in patients with mild-to-moderate (87) PCT Pub. No.: WO2013/030725 hypertension: a randomized, parallel-group, multicentre comparison PCT Pub. Date: Mar. 7, 2013 with losartan plus amlodipine. Pareek et al., Clin Drug Investig. 2010:30(2): 123-131. (65) Prior Publication Data A clinical trial to study the effects of two drugs Olmesartan and US 2014/O3O2125 A1 Oct. 9, 2014 metoprolol in patients with high blood pressure and heart disease. Mohan. Clinical Trials Registry—India, Aug. 8, 2011. retrieved on (30) Foreign Application Priority Data Nov. 23, 2012. cited in the application and in the International Search Report. Aug. 26, 2011 (IN) ........................ IN2O11MU2395A Aug. 26, 2011 (IN) ........................ IN2O11MU2399A * cited by examiner Aug. 27, 2011 (IN) ........................ IN2O11MU2411A Primary Examiner — Micah-Paul Young (51) Int. Cl. (74) Attorney, Agent, or Firm — Bio Intellectual Property A6 IK 9/22 (2006.01) Services LLC (Bio IPS); O. (Sam) Zaghmout A6 IK 3/448 (2006.01) A6 IK3I/38 (2006.01) (57) ABSTRACT A6 IK 3/40 (2006.01) There is provided a once-a-day therapeutically synergistic A6 IK 3/4I (2006.01) pharmaceutical dosage form for treatment of cardiovascular A6 IK 45/06 (2006.01) disorders, wherein the dosage form comprises a fixed dose (52) U.S. Cl. combination of metoprolol in extended release form and one CPC ......... A6 IK3I/4418 (2013.01); A61K 3 1/138 or more calcium channel blocker, angiotensin II receptor (2013.01); A61K 31/40 (2013.01); A61 K3I/41 blocker or angiotensin converting enzyme inhibitor along (2013.01); A61K 45/06 (2013.01) with one or more rate controlling excipient. (58) Field of Classification Search CPC .......... A61K 9/14: A61K 9/141; A61 K9/16; 7 Claims, No Drawings US 9,446,032 B2 1. 2 METHODS FOR TREATING Beta-blocker, for example, metoprolol acts by blocking CARDOVASCULAR DISORDERS the adrenergic stimulation of the heart and thus reduces the oxygen demand of the cardiac tissue. Apparently, this FIELD OF THE INVENTION explains their beneficial effects in angina pectoris and car dioprotective action in myocardial infarction. In addition, The present invention relates to a once-a-day therapeuti beta-blockers normalize blood pressure in a large proportion cally synergistic pharmaceutical dosage form for treatment of patients with arterial hypertension, which probably is due of cardiovascular disorders, wherein the dosage form com to an additional action on the control of peripheral resistance prises a fixed dose combination of metoprolol in extended to blood-flow. release form and one or more calcium channel blocker, 10 Metoprolol (Formula I) is a beta1-selective (cardioselec angiotensin II receptor blocker or angiotensin converting tive) adrenoreceptor-blocking agent. It is commercially enzyme (ACE) inhibitor along with one or more rate con available in two salt forms; one of them is tartrate salt trolling excipient. available as Lopressor(R) tablets and the other is succinate salt available as ToprolR-XL tablets. The ToprolR-XL tab BACKGROUND OF THE INVENTION 15 lets contain 23.75 mg, 47.5 mg, 95 mg and 190 mg of metoprolol Succinate equivalent to 25 mg, 50 mg, 100 mg “Cardiovascular disease or disorder” is intended to mean and 200 mg of metoprolol tartrate, USP, respectively. Meto any cardiovascular disease or disorder known in the art, prolol is indicated in the treatment of hypertension, heart including congestive heart failure, complications associated failure and angina pectoris. with diabetes mellitus, hyperhomocysteinemia, hypercho Initial therapy with a diuretic or beta-blocker has been the lesterolemia, atherosclerosis, inflammatory heart disease, usual first approach for treating cardiovascular disorders. valvular heart disease, restenosis, hypertension (e.g. pulmo ACE inhibitors, calcium channel blockers and angiotensin nary hypertension, labile hypertension, idiopathic hyperten receptors blockers are also effective as first-line therapy. The Sion, low-renin hypertension, salt-sensitive hypertension, physician is therefore required to choose from above classes low-renin, salt-sensitive hypertension, thromboembolic pull 25 of agents for initial therapy. monary hypertension; pregnancy-induced hypertension; Calcium channel blockers play important role in contrac renovascular hypertension; hypertension-dependent end tile processes of cardiac muscle and vascular Smooth muscle stage renal disease, hypertension associated with cardiovas by regulating the movement of extracellular calcium ions cular Surgical procedures, hypertension with left ventricular into these cells through specific ion channels. Calcium hypertrophy, and the like), diastolic dysfunction, coronary 30 channel blockers work by blocking Voltage-gated calcium artery disease, myocardial infarctions, cerebral infarctions, channels (VGCCs) in cardiac muscle and blood vessels. This arteriosclerosis, atherogenesis, cerebrovascular disease, decreases intracellular calcium leading to a reduction in angina (including chronic, stable, unstable and variant (Prin muscle contraction. In the heart, a decrease in calcium Zmetal) angina pectoris), aneurysm, ischemic heart disease, available for each beat results in a decrease in cardiac cerebral ischemia, myocardial ischemia, thrombosis, platelet 35 contractility. In blood vessels, a decrease in calcium results aggregation, platelet adhesion, Smooth muscle cell prolif in less contraction of the vascular Smooth muscle and eration, Vascular or non-vascular complications associated therefore an increase in arterial diameter (CCBs do not work with the use of medical devices, vascular or non-vascular on venous Smooth muscle) a phenomenon called vasodila wall damage, peripheral vascular disease, neointimal hyper tion. plasia following percutaneous transluminal coronary angio 40 Angiotensin II receptor blockers (ARBs), also known as graph, vascular grafting, coronary artery bypass Surgery, angiotensin II receptor antagonists, ATI-receptor antagonists thromboembolic events, post-angioplasty restenosis, coro or 'sartans', are a group of drugs which modulate the nary plaque inflammation, embolism, stroke, shock, arrhyth renin-angiotensin-aldosterone system. Their main uses are mia, atrial fibrillation or atrial flutter, thrombotic occlusion in the treatment of hypertension (high blood pressure), and reclusion cerebrovascular incidents, and the like. 45 diabetic nephropathy (kidney damage due to diabetes) and Many individuals are at an elevated risk of suffering congestive heart failure. Angiotensin II receptor blockers, serious to life-threatening cardiovascular events, including block the activation of angiotensin II AT1 receptors. Block infarction (heart attack), cardiac arrest, congestive heart ade of AT1 receptors directly causes vasodilation, reduces failure, stroke, peripheral vascular disease and/or claudica secretion of vasopressin, and reduces production and secre tion. The risk factors are numerous and widespread through 50 tion of aldosterone, amongst other actions. The combined out the world population. They include cigarette Smoking, effect reduces blood pressure. diabetes, hypercholesterolemia (high serum cholesterol), ACE inhibitors or angiotensin-converting enzyme inhibi hypertension, angina, Systemic lupus erythematosus, prior tors are a group of drugs used primarily for the treatment of heart attacks or strokes, hemodialysis, hyperhomocysteine hypertension (high blood pressure) and congestive heart levels, obesity, sedentary lifestyle, receiving an organ trans 55 failure, although they may also be prescribed for cardiac plant, atherosclerosis, and others. There is a need for a safe failure, diabetic nephropathy, renal disease, Systemic scle and convenient pharmaceutical formulation that would rosis, left ventricular hypertrophy and other disorders. Origi effectively reduce the risk of incurring a cardiovascular nally synthesized from compounds found in pit viper event in individuals who have these risk factors. Venom, they inhibit angiotensin-converting enzyme (ACE), The treatments and drugs discovered or known in the art 60 a component of the blood pressure-regulating renin-angio for cardiovascular
Load more

Recommended publications
  • Supplementary Appendix 1. Search Strategy for the Systematic Review and Meta-Analysis
    BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) Thorax Supplementary Appendix 1. Search strategy for the systematic review and meta-analysis # COVID-19 AND (ACEI or ARB) Pubmed #1. COVID-19 ((((novel[Title/Abstract]) AND (((corona[Title/Abstract]) AND virus[Title/Abstract]) OR (coronavirus[Title/Abstract]))) OR ((COVID[Title/Abstract]) OR (COVID-19[Title/Abstract]) OR (nCoV[Title/Abstract]) OR (2019-nCoV[Title/Abstract]) OR (Novel Coronavirus Pneumon.ia[Title/Abstract]) OR (NCP[Title/Abstract]) OR (severe acute respiratory infection[Title/Abstract]) OR (SARI[Title/Abstract]) OR (SARS-CoV-2[Title/Abstract]))) #2. ARB (("Angiotensin Receptor Antagonists"[Mesh]) OR (((angiotensin receptor blocker[Title/Abstract]) OR angiotensin receptor blockers[Title/Abstract]) OR ARB.*[Title/Abstract]) OR (((angiotensin[Title/Abstract]) AND receptor[Title/Abstract]) AND (antagonist.*[Title/Abstract] OR inhibitor.*[Title/Abstract] OR blocker.*[Title/Abstract]))) OR (ARB[Title/Abstract]) OR (olmesartan[Title/Abstract]) OR (valsartan[Title/Abstract]) OR (eprosartan[Title/Abstract]) OR (irbesartan[Title/Abstract]) OR (candesartan[Title/Abstract]) OR (losartan[Title/Abstract]) OR (telmisartan[Title/Abstract]) OR (azilsartan[Title/Abstract]) OR (tasosartan[Title/Abstract]) OR (embusartan[Title/Abstract]) OR (forasartan[Title/Abstract]) OR (milfasartan[Title/Abstract]) OR (saprisartan[Title/Abstract]) OR (zolasartan[Title/Abstract])
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • WO 2017/055924 A2 6 April 2017 (06.04.2017) W P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/055924 A2 6 April 2017 (06.04.2017) W P O PCT (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 33/04 (2006.01) A61K 9/00 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, PCT/IB2016/0015 10 KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (22) International Filing Date: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 28 September 2016 (28.09.201 6) OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (25) Filing Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (26) Publication Language: English ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 62/233,906 28 September 2015 (28.09.2015) US kind of regional protection available): ARIPO (BW, GH, 62/233,941 28 September 2015 (28.09.2015) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: M.G.
    [Show full text]
  • Ovid MEDLINE(R)
    Supplementary material BMJ Open Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily <1946 to September 16, 2019> # Searches Results 1 exp Hypertension/ 247434 2 hypertens*.tw,kf. 420857 3 ((high* or elevat* or greater* or control*) adj4 (blood or systolic or diastolic) adj4 68657 pressure*).tw,kf. 4 1 or 2 or 3 501365 5 Sex Characteristics/ 52287 6 Sex/ 7632 7 Sex ratio/ 9049 8 Sex Factors/ 254781 9 ((sex* or gender* or man or men or male* or woman or women or female*) adj3 336361 (difference* or different or characteristic* or ratio* or factor* or imbalanc* or issue* or specific* or disparit* or dependen* or dimorphism* or gap or gaps or influenc* or discrepan* or distribut* or composition*)).tw,kf. 10 or/5-9 559186 11 4 and 10 24653 12 exp Antihypertensive Agents/ 254343 13 (antihypertensiv* or anti-hypertensiv* or ((anti?hyperten* or anti-hyperten*) adj5 52111 (therap* or treat* or effective*))).tw,kf. 14 Calcium Channel Blockers/ 36287 15 (calcium adj2 (channel* or exogenous*) adj2 (block* or inhibitor* or 20534 antagonist*)).tw,kf. 16 (agatoxin or amlodipine or anipamil or aranidipine or atagabalin or azelnidipine or 86627 azidodiltiazem or azidopamil or azidopine or belfosdil or benidipine or bepridil or brinazarone or calciseptine or caroverine or cilnidipine or clentiazem or clevidipine or columbianadin or conotoxin or cronidipine or darodipine or deacetyl n nordiltiazem or deacetyl n o dinordiltiazem or deacetyl o nordiltiazem or deacetyldiltiazem or dealkylnorverapamil or dealkylverapamil
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Angiotensin-Converting Enzyme (ACE)
    Angiotensin-converting Enzyme (ACE) Angiotensin-converting enzyme (ACE) indirectly increases blood pressure by causing blood vessels to constrict. ACE does that by converting angiotensin I to angiotensin II, which constricts the vessels. ACE, angiotensin I and angiotensin II are part of the renin-angiotensin system (RAS), which controls blood pressure by regulating the volume of fluids in the body. ACE is secreted in the lungs and kidneys by cells in the endothelium (inner layer) of blood vessels. It has two primary functions: ACE catalyses the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor in a substrate concentration-dependent manner. ACE degrades bradykinin, a potent vasodilator, and other vasoactive peptides. These two actions make ACE inhibition a goal in the treatment of conditions such as high blood pressure, heart failure, diabetic nephropathy, and type 2 diabetes mellitus. Inhibition of ACE (by ACE inhibitors) results in the decreased formation of angiotensin II and decreased metabolism of bradykinin, leading to systematic dilation of the arteries and veins and a decrease in arterial blood pressure. www.MedChemExpress.com 1 Angiotensin-converting Enzyme (ACE) Inhibitors & Activators (R)-MLN-4760 Alamandine Cat. No.: HY-19414A Cat. No.: HY-P3108 (R)-MLN-4760, the R-enantiomer of MLN-4760, is an Alamandine, a member of the renin-angiotensin ACE2 inhibitor, with an IC50 of 8.4 μM. system (RAS), a vasoactive peptide, is an (R)-MLN-4760 is the less active isomer. endogenous ligand of the G protein-coupled receptor MrgD. Alamandine targets to protect the kidney and heart through anti-hypertensive actions. Purity: >98% Purity: 98.95% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg, 25 mg Size: 5 mg Angiotensin (1-7) Angiotensin (1-7) (acetate) (Ang-(1-7)) Cat.
    [Show full text]
  • Angiotensin Converting Enzyme Inhibitors in the Treatment of Hypertension
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Publications of the IAS Fellows CHEMISTRY – STRUCTURE, SYNTHESIS AND DYNAMICS Angiotensin converting enzyme inhibitors in the treatment of hypertension Bhaskar J. Bhuyan and Govindasamy Mugesh* Department of Inorganic and Physical Chemistry, Indian Institute of Science, Bangalore 560 012, India verting enzyme’ (ACE). Further, ACE is also responsible Angiotensin converting enzyme (ACE) catalyses the conversion of angiotensin I (Ang I) to angiotensin II for the elevation of BP by cleaving the terminal dipeptide (Phe–Arg) of vasodilator hormone bradykinin to its (Ang II). The ACE activity directly related to hyperten- 5,6 sion as Ang II is the blood pressure regulating hormone. inactive form (bradykinin 1–7, Figure 1) . Therefore, ACE inhibitors are a major class of anti- Involvement of RAS in elevation of BP was reported hypertensive drugs. Captopril, chemical name, was for the first time by Tigerstedt and Bergman7, who have the first orally active ACE inhibitory antihypertensive shown that the saline extract of kidney contains some drug, discovered in 1977. Since then, a number of such vasopressor (material that increases BP) activity. It was drugs have been synthesized. Enzyme-inhibitor bound named ‘renin’ as it was extracted from kidney. In 1940s, crystal structural studies reveal a great deal of under- Braun-Mendez and co-workers8 discovered that renin standing about the interactions of the inhibitors at the catalyses the formation of the actual pressor agent, the active site of ACE. This can be helpful in the rational ‘angiotensinogen’ (also called hypertensinogen).
    [Show full text]
  • Supplementary Appendix 1. Search Strategy for the Systematic Review and Meta-Analysis
    BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) Thorax Supplementary Appendix 1. Search strategy for the systematic review and meta-analysis # COVID-19 AND (ACEI or ARB) Pubmed #1. COVID-19 ((((novel[Title/Abstract]) AND (((corona[Title/Abstract]) AND virus[Title/Abstract]) OR (coronavirus[Title/Abstract]))) OR ((COVID[Title/Abstract]) OR (COVID-19[Title/Abstract]) OR (nCoV[Title/Abstract]) OR (2019-nCoV[Title/Abstract]) OR (Novel Coronavirus Pneumon.ia[Title/Abstract]) OR (NCP[Title/Abstract]) OR (severe acute respiratory infection[Title/Abstract]) OR (SARI[Title/Abstract]) OR (SARS-CoV-2[Title/Abstract]))) #2. ARB (("Angiotensin Receptor Antagonists"[Mesh]) OR (((angiotensin receptor blocker[Title/Abstract]) OR angiotensin receptor blockers[Title/Abstract]) OR ARB.*[Title/Abstract]) OR (((angiotensin[Title/Abstract]) AND receptor[Title/Abstract]) AND (antagonist.*[Title/Abstract] OR inhibitor.*[Title/Abstract] OR blocker.*[Title/Abstract]))) OR (ARB[Title/Abstract]) OR (olmesartan[Title/Abstract]) OR (valsartan[Title/Abstract]) OR (eprosartan[Title/Abstract]) OR (irbesartan[Title/Abstract]) OR (candesartan[Title/Abstract]) OR (losartan[Title/Abstract]) OR (telmisartan[Title/Abstract]) OR (azilsartan[Title/Abstract]) OR (tasosartan[Title/Abstract]) OR (embusartan[Title/Abstract]) OR (forasartan[Title/Abstract]) OR (milfasartan[Title/Abstract]) OR (saprisartan[Title/Abstract]) OR (zolasartan[Title/Abstract])
    [Show full text]
  • Drug and Medication Classification Schedule
    KENTUCKY HORSE RACING COMMISSION UNIFORM DRUG, MEDICATION, AND SUBSTANCE CLASSIFICATION SCHEDULE KHRC 8-020-1 (11/2018) Class A drugs, medications, and substances are those (1) that have the highest potential to influence performance in the equine athlete, regardless of their approval by the United States Food and Drug Administration, or (2) that lack approval by the United States Food and Drug Administration but have pharmacologic effects similar to certain Class B drugs, medications, or substances that are approved by the United States Food and Drug Administration. Acecarbromal Bolasterone Cimaterol Divalproex Fluanisone Acetophenazine Boldione Citalopram Dixyrazine Fludiazepam Adinazolam Brimondine Cllibucaine Donepezil Flunitrazepam Alcuronium Bromazepam Clobazam Dopamine Fluopromazine Alfentanil Bromfenac Clocapramine Doxacurium Fluoresone Almotriptan Bromisovalum Clomethiazole Doxapram Fluoxetine Alphaprodine Bromocriptine Clomipramine Doxazosin Flupenthixol Alpidem Bromperidol Clonazepam Doxefazepam Flupirtine Alprazolam Brotizolam Clorazepate Doxepin Flurazepam Alprenolol Bufexamac Clormecaine Droperidol Fluspirilene Althesin Bupivacaine Clostebol Duloxetine Flutoprazepam Aminorex Buprenorphine Clothiapine Eletriptan Fluvoxamine Amisulpride Buspirone Clotiazepam Enalapril Formebolone Amitriptyline Bupropion Cloxazolam Enciprazine Fosinopril Amobarbital Butabartital Clozapine Endorphins Furzabol Amoxapine Butacaine Cobratoxin Enkephalins Galantamine Amperozide Butalbital Cocaine Ephedrine Gallamine Amphetamine Butanilicaine Codeine
    [Show full text]
  • Drugs for Primary Prevention of Atherosclerotic Cardiovascular Disease: an Overview of Systematic Reviews
    Supplementary Online Content Karmali KN, Lloyd-Jones DM, Berendsen MA, et al. Drugs for primary prevention of atherosclerotic cardiovascular disease: an overview of systematic reviews. JAMA Cardiol. Published online April 27, 2016. doi:10.1001/jamacardio.2016.0218. eAppendix 1. Search Documentation Details eAppendix 2. Background, Methods, and Results of Systematic Review of Combination Drug Therapy to Evaluate for Potential Interaction of Effects eAppendix 3. PRISMA Flow Charts for Each Drug Class and Detailed Systematic Review Characteristics and Summary of Included Systematic Reviews and Meta-analyses eAppendix 4. List of Excluded Studies and Reasons for Exclusion This supplementary material has been provided by the authors to give readers additional information about their work. © 2016 American Medical Association. All rights reserved. 1 Downloaded From: https://jamanetwork.com/ on 09/28/2021 eAppendix 1. Search Documentation Details. Database Organizing body Purpose Pros Cons Cochrane Cochrane Library in Database of all available -Curated by the Cochrane -Content is limited to Database of the United Kingdom systematic reviews and Collaboration reviews completed Systematic (UK) protocols published by by the Cochrane Reviews the Cochrane -Only systematic reviews Collaboration Collaboration and systematic review protocols Database of National Health Collection of structured -Curated by Centre for -Only provides Abstracts of Services (NHS) abstracts and Reviews and Dissemination structured abstracts Reviews of Centre for Reviews bibliographic
    [Show full text]
  • Wo 2011/060945 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 26 May 2011 (26.05.2011) WO 201 1/060945 A2 (51) International Patent Classification: (72) Inventor; and A61K 9/16 (2006.01) A61K 9/50 (2006.01) (75) Inventor/Applicant (for US only): PARENTE DUENA, A61K 9/48 (2006.01) A61K 31/403 (2006.01) Antonio [ES/ES]; Passeig Can Sagrera 17-21, E-08960 San Just Desvern - Barcelona (ES). (21) International Application Number: PCT/EP20 10/007025 (74) Agent: CARVAJAL Y URQUIJO, Isabel; Clarke, Mod- et & Co., C/Goya 11, E-28001 Madrid (ES). (22) International Filing Date: 19 November 2010 (19.1 1.2010) (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, English (25) Filing Language: AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (26) Publication Langi English CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (30) Priority Data: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, 200931024 20 November 2009 (20.1 1.2009) ES KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (71) Applicants (for all designated States except US): GP ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, PHARM, S.A. [ES/ES]; Poligono Industrial Els Vinyets - NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, Els Fogars, Ctra.
    [Show full text]
  • Systematic Evidence Review from the Blood Pressure Expert Panel, 2013
    Managing Blood Pressure in Adults Systematic Evidence Review From the Blood Pressure Expert Panel, 2013 Contents Foreword ............................................................................................................................................ vi Blood Pressure Expert Panel ..............................................................................................................vii Section 1: Background and Description of the NHLBI Cardiovascular Risk Reduction Project ............ 1 A. Background .............................................................................................................................. 1 Section 2: Process and Methods Overview ......................................................................................... 3 A. Evidence-Based Approach ....................................................................................................... 3 i. Overview of the Evidence-Based Methodology ................................................................. 3 ii. System for Grading the Body of Evidence ......................................................................... 4 iii. Peer-Review Process ....................................................................................................... 5 B. Critical Question–Based Approach ........................................................................................... 5 i. How the Questions Were Selected ................................................................................... 5 ii. Rationale for the Questions
    [Show full text]